BCAB Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: Chartmill - Mentions: XRTX ADAP FPAY CELC ...

These stocks are moving in today's session

2 days ago - By: BioAtla, Inc.

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

17 days ago - By: BioAtla, Inc.

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

20 days ago - By: Benzinga - Mentions: IBIO ABP AVR STTK ...

12 Health Care Stocks Moving In Monday's After-Market Session

20 days ago - By: BioAtla, Inc.

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

a month ago - By: BioAtla, Inc.

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

3 months ago - By: The Motley Fool

BioAtla (BCAB) Q2 Loss Narrows 27%

3 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

3 months ago - By: BioAtla, Inc.

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

4 months ago - By: BioAtla, Inc.

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO)

6 months ago - By: BioAtla, Inc.

BioAtla to Participate in the Citizens Life Sciences Conference

6 months ago - By: BioAtla, Inc.

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

7 months ago - By: BioAtla, Inc.

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

7 months ago - By: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

8 months ago - By: BioAtla, Inc.

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

8 months ago - By: BioAtla, Inc.

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

8 months ago - By: BioAtla, Inc.

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

a year ago - By: BioAtla, Inc.

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

a year ago - By: BioAtla, Inc.

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

a year ago - By: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

a year ago - By: BioAtla, Inc.

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

a year ago - By: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

a year ago - By: BioAtla, Inc.

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

a year ago - By: Context Therapeutics Inc. - Mentions: CNTX

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

a year ago - By: InvestorPlace

BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024

a year ago - By: BioAtla, Inc.

BIOATLA INC (BCAB) Stock News

BCAB Latest News, Press Relases and Analysis

These stocks are moving in today's session

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

12 Health Care Stocks Moving In Monday's After-Market Session

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

BioAtla (BCAB) Q2 Loss Narrows 27%

Earnings Scheduled For August 7, 2025

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO)

BioAtla to Participate in the Citizens Life Sciences Conference

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BCAB Stock Earnings: BioAtla Meets EPS for Q2 2024

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day